SCHEMBL22295397

SCHEMBL22295397

COc1cc2nccc(Oc3cc(F)c(N)cc3F)c2cc1C(N)=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.57
AURKB Q96GD4 5/20 0.57
MET P08581 5/20 0.57
AURKA O14965 4/20 0.57
TEK Q02763 4/20 0.57
AXL P30530 4/20 0.52
PDGFRB P09619 2/20 0.51
PDGFRA P16234 2/20 0.51
ABL1 P00519 2/20 0.50
LCK P06239 1/20 0.50
LYN P07948 1/20 0.50
MERTK Q12866 1/20 0.49
SRC P12931 3/20 0.48
TGFBR1 P36897 3/20 0.48
RET P07949 2/20 0.48
RIPK2 O43353 1/20 0.48
ERN1 O75460 1/20 0.48
STK10 O94804 1/20 0.48
MAP3K6 O95382 1/20 0.48
ESR1 P03372 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22295393 0.91 KDR (0.56) KDRAURKBMETAURKATEK
SCHEMBL21083204 0.87 KDR (0.57) KDRAURKBMETAURKATEK
SCHEMBL14742900 0.86 PDGFRA (0.56) KDRAXLPDGFRBPDGFRASRC
SCHEMBL1893988 0.86 KDR (0.67) KDRAURKBMETAURKATEK
SCHEMBL25028726 0.85 KDR (0.55) KDRAURKBMETAURKATEK
SCHEMBL22295341 0.85 PDGFRB (0.58) KDRAURKBMETAURKATEK
SCHEMBL25028724 0.84 KDR (0.54) KDRAURKBMETAURKATEK
SCHEMBL19957388 0.83 KDR (0.63) KDRAURKBMETAURKATEK
SCHEMBL25029459 0.83 KDR (0.51) KDRAURKBMETAURKATEK
SCHEMBL25028717 0.83 PDGFRB (0.54) KDRAURKBMETAURKATEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11161817-B2 Quinoline derivative and use thereof as tyrosine kinase inhibitor Chongqing Pharmaceutical Industrial Research Institute Co. Ltd. (CN) 2021-11-02 US disclosed
EP-3689351-A1 QUINOLINE DERIVATIVE AND APPLICATION THEREOF AS TYROSINE KINASE INHIBITOR Medshine Discovery Inc. (CN) 2020-08-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11161817-B2 Quinoline derivative and use thereof as tyrosine kinase inhibitor ABL1, JAK2, FLT3 KDR 244/4885AURKB 265/4885MET 674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.